R. Beers

发表

An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes

Ira Pastan, Masanori Onda, I. Pastan, 2008, Proceedings of the National Academy of Sciences.

Characterization of the B Cell Epitopes Associated with a Truncated Form of Pseudomonas Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer Patients1

James J. Vincent, I. Pastan, Byungkook Lee, 2006, The Journal of Immunology.

New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA

Mitchell Ho, Ira Pastan, Masanori Onda, 2005, Clinical Cancer Research.

Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII‐specific scFv

I. Pastan, D. Bigner, M. Zalutsky, 2000, International journal of cancer.

Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia

I. Pastan, R. Beers, T. Bera, 2018, Toxins.

Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display.

I. Pastan, R. Beers, C. Pegram, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display.

I. Pastan, D. Bigner, P. Chowdhury, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer.

I. Pastan, P. Chowdhury, R. Beers, 2001, Molecular cancer therapeutics.

A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity

I. Pastan, Jingli Zhang, M. Onda, 2012, Molecular Cancer Therapeutics.

A Recombinant Immunotoxin Targeting CD22 With Low Immunogenicity, Low Nonspecific Toxicity, and High Antitumor Activity in Mice

I. Pastan, M. Onda, R. Beers, 2010, Journal of immunotherapy.

Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity.

I. Pastan, R. Beers, Xing-yan Du, 2008, Cancer research.

PatientsImmunotoxins for the Treatment of Cancer Exotoxin (PE38) Used to Make Pseudomonas Associated with a Truncated Form of Characterization of the B Cell Epitopes

James J. Vincent, I. Pastan, Byungkook Lee, 2006 .

The PATE gene is expressed in the accessory tissues of the human male genital tract and encodes a secreted sperm-associated protein.

I. Pastan, T. Ise, S. Nagata, 2005, Reproduction.

Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.

Mitchell Ho, I. Pastan, Jun Liu, 2007, Bioconjugate chemistry.

Stabilization of a recombinant Fv fragment by base-loop interconnection and V(H)-V(L) permutation.

I. Pastan, U. Brinkmann, G. Vasmatzis, 1997, Journal of molecular biology.

Recombinant immunotoxins in the treatment of cancer.

I. Pastan, R. Beers, T. Bera, 2004, Methods in molecular biology.

Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers

I. Pastan, U. Brinkmann, P. Chowdhury, 1997, International journal of cancer.

Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors

I. Pastan, Jingli Zhang, R. Hassan, 2015, Molecular Cancer Therapeutics.

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin

Mitchell Ho, I. Pastan, P. Azadi, 2022, Proceedings of the National Academy of Sciences of the United States of America.

NGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostate.

Byungkook Lee, Yoonsoo Hahn, Ira Pastan, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes

I. Pastan, Byungkook Lee, R. Kreitman, 2011, Proceedings of the National Academy of Sciences.

Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity.

I. Pastan, P. Chowdhury, R. Beers, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A

Ronit Mazor, Ira Pastan, I. Pastan, 2012, Proceedings of the National Academy of Sciences.

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes

D. Baker, I. Pastan, Byungkook Lee, 2014, Proceedings of the National Academy of Sciences.

Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.

I. Pastan, G. Salvatore, R. Kreitman, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments.

I. Pastan, R. Kreitman, S. Nagata, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv.

I. Pastan, G. Vasmatzis, P. Chowdhury, 1998, Journal of molecular biology.

Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin.

I. Pastan, I. Fidler, S. Yano, 2000, International journal of oncology.